Form 4: REGENXBIO CEO Curran Simpson Receives Stock Options and Restricted Stock Units
SEC Form 4 Filing
REGENXBIO's CEO, Curran Simpson, was granted stock options and restricted stock units (RSUs) on July 1, 2024, according to a recent SEC filing.
Summary
- Curran Simpson, CEO of REGENXBIO Inc., received 56,458 shares of common stock and 272,189 stock options on July 1, 2024.
- The restricted stock units (RSUs) vest in equal installments over four years, starting July 1, 2024, contingent upon continuous service.
- The stock options also vest over four years, with 1/4 vesting after 12 months of continuous service and the remainder vesting monthly thereafter, also contingent upon continuous service.
- The stock options have an exercise price of $11.07 and expire in 10 years.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. The sentiment is neutral to slightly positive.
Positives
- The grant of stock options and RSUs aligns the CEO's interests with those of the shareholders, incentivizing long-term value creation.
- The vesting schedules encourage continuous service and commitment from the CEO.
Risks
- The value of the stock options and RSUs is dependent on the future performance of REGENXBIO's stock price.
- If the CEO leaves the company before the options and RSUs fully vest, a portion of the awards may be forfeited.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedules of the stock options and RSUs.
Industry Context
Stock option and RSU grants are a common practice in the biotechnology industry to attract and retain top executive talent and align their interests with those of shareholders. The vesting schedules are typical for such grants.
Comparison to Industry Standards
- Executive compensation packages in the biotech industry often include a mix of salary, bonus, stock options, and restricted stock units.
- Vesting schedules for stock options and RSUs typically range from three to five years, with annual or monthly vesting increments.
- Companies like Amgen, Gilead Sciences, and Biogen also utilize similar compensation structures for their executives.
Stakeholder Impact
- Shareholders may view the grant of stock options and RSUs positively as it incentivizes the CEO to increase shareholder value.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 07/01/2024 | Date of transaction, vesting commencement date for RSU and stock options. |
| 07/03/2024 | Date of signature by attorney-in-fact. |
| 07/01/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.